Skip to content

CMO Login
Collaborators Login

Home
Who We Are
- About Us
What We Do
- Programs & Services
- Technologies
News
Contact Us
- Privacy Policies

Tau Imaging with 18F-MK6240 across the Alzheimer’s Disease spectrum

Tau deposition plays a critical role over cognition and neurodegeneration in Alzheimer’s disease (AD)

Post navigation

Previous: Comparing tau status determined via plasma pTau181, pTau231 and [ 18 F]MK6240 tau-PET

Next: Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer’s disease

Search for:

Recent Posts

Cerveau Technologies Inc. Signs Agreement with Roche to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
Cerveau Technologies, Inc. and Nihon Med-Physics Co., Ltd. Announce Manufacturing Service Agreement for [18F]MK-6240 in Japan
New PET imaging tracer helps spot signs of Alzheimer’s disease years before symptoms appear
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Cerveau Technologies, Inc. announces Formation of Scientific Advisory Board

Recent Comments

Archives

March 2022
February 2022
June 2021
September 2020
May 2020
March 2020
December 2019
November 2019
September 2019
May 2019
March 2019
February 2019
December 2018
September 2018
August 2018
June 2018
May 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
June 2017
May 2017
March 2017
February 2017
January 2017

Categories

PRESS RELEASE
Uncategorized

Meta

Log in
Entries feed
Comments feed
WordPress.org

308 N. Peters Road Suite #201
Knoxville, TN 37922

info@cerveautechnologies.com

© Copyright 2022 Cerveau Technologies. All Rights Reserved.

Privacy Policies

Technology Web Design by Thomas Digital

Home
Who We Are
- About Us
What We Do
- Programs & Services
- Technologies
News
Contact Us
- Privacy Policies